EyeCRO are Experts in preclinical efficacy studies in ophthalmic retinopathy, pharmacokinetics, both in vivo and in vitro for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in retina preclinical efficacy, oxygen-induced retinopathy, and ophthalmic pharmacokinetics for clinical and precise formulation services and trial batteries. EyeCRO is a preclinical ophthalmic research organization focused on studies in Laser CNV, Retina preclinical efficacy, and Ophthalmic toxicology for clinical and precise formulation services.

Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research

MiDROPS™

The Microemulsion Drug Ocular Penetration System (MiDROPS™) is a transformative technology for the development of eyedrop formulations.  This patented platform allows for the preparation and delivery of lipophilic agents to tissues in both the front and back of the eye.  MiDROPS™ are prepared using materials already approved by the US Food and Drug Administration for use in ophthalmic products, and by nature are intrinsically thermo-stable.

 

In-Vivo

EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

Surgeons perform world’s first operation inside the eye using a robot

Robert MacLaren, Professor of Ophthalmology. assisted by Dr Thomas Edwards, Nuffield Medical Fellow, … Read More

Allergan Makes an Eye-Opening Acquisition

Global pharmaceutical company Allergan (NYSE:AGN) may have just revealed its plans for the future. … Read More

Curing blindness by repairing corneas with invisible films

The University of Melbourne–lead team of researchers have grown corneal cells on a layer of film … Read More

More News

Tuesday, September 27th, 2016 at 3:57am
RT @Eye_Institute: Baseline HbA1c may affect response to anti-VEGF treatment in real-world setting #diabetic macular oedema #DME https://t…
Monday, September 26th, 2016 at 7:43pm
RT @_BrightFocus: Honored to support #RD2016 and to provide travel grants for innovative scientists seeking cures for retinal diseases, inc…
Monday, September 26th, 2016 at 12:11pm
RT @NatEyeInstitute: #DYK there are about 130 million cells in the #retina? Learn more about the visual system: https://t.co/LJKaxUy1SE
Sunday, September 25th, 2016 at 11:56pm
RT @OphthoRR: Patients with Primary Open-Angle Glaucoma May Develop Ischemic Heart Disease More Often than Those without Glaucoma https://t…
Ophthalmic Contract Research